A $15 million international study is investigating patients in long-term remission to understand whether lupus can truly switch off — and what that reveals about the immune system.
By explicitly specifying treatment effects and intercurrent events, estimands help sponsors, clinicians, and regulators work from a shared understanding.
The milestone marks meaningful progress toward developing new therapeutic options for Alport syndrome, with first-patient dosing expected in early 2026.
New study finds limited value from nearly one-third of clinical trial procedures and associated data, highlighting opportunity for more patient-centric trial design
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.